Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MDT
Strong BuyFull HouseAPPROVEMedtronic plc · Healthcare · Ireland · $116.8B · Avg Vol: $691M/d
Medtronic clears the calibrated bar. All three legs are above the floor (Q64 V57 M53) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q64 is the strongest part of the case.
COMPANY DESCRIPTION
Medtronic plc is a global leader in medical technology, developing, manufacturing, and marketing a broad portfolio of medical devices and therapies for various chronic diseases, including cardiovascular, diabetes, and surgical solutions. The company maintains a strong competitive advantage through its extensive intellectual property, robust R&D pipeline, and deep clinical relationships, driving innovation in patient care worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 31.2B | 32.4B | 33.5B | 36.4B | 5.2% | 37.5B | 39.1B | 40.4B | 5.5% |
| EPS | 3.75 | 2.83 | 2.77 | 3.63 | 3.75 | 0.0% | 4.06 | 4.05 | 4.34 | 7.6% |
| Shares | — | 1.3B | 1.3B | 1.3B | 1.3B | -3.8% | 1.3B | — | — | — |
| Debt | — | 24.4B | 25.0B | 28.5B | 28.0B | 4.7% | 29.1B | — | — | — |
| Equity | — | 51.5B | 50.2B | 48.0B | 49.5B | -1.3% | — | — | — | — |
| Op CF | — | 6.0B | 6.8B | 7.0B | 7.3B | 6.7% | 8.0B | — | — | — |
| Inv CF | — | -3.5B | -2.4B | -1.9B | -2.9B | — | — | — | — | — |
| Fin CF | — | -5.0B | -4.5B | -4.4B | -4.8B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MDT | Medtronic plc(you) | $116.8B | 82 | Strong Buy |
| DXCM | DexCom, Inc. | $34.3B | 84 | Strong Buy |
| SYK | Stryker Corporation | $126.8B | 58 | Hold |
| ABT | Abbott Laboratories | $194.6B | 61 | Hold |
| PHG | Koninklijke Philips N.V. | $26.1B | 85 | Strong Buy |
| EW | Edwards Lifesciences Corporation | $52.0B | 65 | Buy |
| SHL.DE | Siemens Healthineers AG | $51.3B | 63 | Hold |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
| SOON.SW | Sonova Holding AG | $17.2B | 78 | Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%